Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
November 15, 2024 11:02 ET
|
Barinthus Biotherapeutics
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
November 15, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
November 15, 2024 04:30 ET
|
Numab Therapeutics AG; Kaken Pharmaceutical Co., Ltd.
Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
November 14, 2024 16:05 ET
|
Alumis Inc.
Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).
Abivax presents third quarter 2024 key financial information
November 14, 2024 16:01 ET
|
Abivax
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...
Sparian Biosciences Awarded $19.5 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-226 for Opiate Use Disorder/ Opiate Withdrawal Syndrome Through Phase 1 Clinical Development
November 14, 2024 10:06 ET
|
Sparian Biosciences, Inc
Sparian Biosciences announced that it has been awarded a $19.5 million, five-year grant to fund development of SBS-226
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
November 14, 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
November 13, 2024 16:05 ET
|
Alumis Inc.
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
November 13, 2024 16:01 ET
|
Abivax
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq:...
Sparian Biosciences Announces Formation of its Science Advisory Board
November 13, 2024 13:01 ET
|
Sparian Biosciences, Inc
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Sparian Biosciences, Inc. (“Sparian”), a clinical-stage CNS-focused biopharmaceutical company, is proud to announce formation of a Science Advisory Board...